Categories: News

Viemed Healthcare Announces Entry into Remote Patient Monitoring Sector

LAFAYETTE, La., Dec. 21, 2020 (GLOBE NEWSWIRE) — Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX: VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced it has acquired a 5% interest in VeruStat, Inc, a newly created company focusing on remote patient monitoring (“RPM”), for approximately $600,000 using cash on hand.

The investment is part of the Company’s launch into the healthcare technology sector, and will immediately allow the Company’s salesforce to offer a new revenue source to its physician network around the country. RPM platforms allow physicians to bill for safely monitoring patients inside of the home that are struggling with chronic diseases. The VeruStat RPM solution will be placed in the home in conjunction with Viemed’s existing patient engagement platform (“PEP”). Preliminary data indicates that the use of Viemed’s internally developed PEP results in better patient compliance along with labor and workflow efficiencies. The Company is currently expanding the number of patients utilizing the PEP technology.

“The pandemic has revealed a great demand by physicians and patients to safely use technology to provide patient care inside of the home,” said Casey Hoyt, Viemed CEO. “We are excited to be partnering with VeruStat in the RPM space, as their unique solution will fit well with our physician network. While the RPM space is new, it complements our mission of interacting more frequently with chronically ill patients across multiple disease states, even beyond respiratory illnesses. We fully expect the RPM platform to add incremental revenue in 2021 on a standalone basis, while driving new adjacencies and adding to our core respiratory business.”

ABOUT VIEMED HEALTHCARE, INC.

Viemed, through its indirect wholly-owned subsidiaries Sleep Management, L.L.C. and Home Sleep Delivered, L.L.C., is a home medical equipment supplier that provides post-acute respiratory care services in the United States. Sleep Management, L.L.C. focuses on disease management and improving the quality of life for respiratory patients through clinical excellence, education, and technology. Its service offerings are based on effective home treatment with respiratory care practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Home Sleep Delivered, L.L.C. focuses on providing in-home sleep testing for sleep apnea sufferers. Visit our website at www.viemed.com.

For further information, please contact:

Glen Akselrod
Bristol Capital
905-326-1888
glen@bristolir.com

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
investorinfo@viemed.com

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company’s expectations regarding the performance of the remote patient monitoring aspect of its business, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; the impact of the COVID-19 pandemic and the actions taken by governmental authorities, individuals and companies in response to the pandemic on our business, financial condition and results of operations, including on the Company’s patient base and revenues, employees, and equipment and supplies; the Company may be subject to significant capital requirements and operating risks; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of shares in the capital of the Company; the Company’s novel business model; the risk that the clinical application of treatments that demonstrate positive results in a study may not be positively replicated or that such test results may not be predictive of actual treatment results or may not result in the adoption of such treatments by providers; the state of the capital markets; the availability of funds and resources to pursue operations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the impact of the previously disclosed restatement and correction of the Company’s previously issued financial statements; the previously disclosed identified material weakness in the Company’s internal control over financial reporting and the Company’s ability to remediate that material weakness; the initiation of legal or regulatory proceedings with respect to the restatement and corrections; the adverse effects on the Company’s business, results of operations, financial condition and stock price, as a result of the restatement and correction process; the Company’s status as an emerging growth company and a foreign private issuer; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the recent COVID-19 pandemic, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

Staff

Recent Posts

PMI Foods Donates 5,000 Pounds of Prime Ribs to City of Refuge to Help Victims of Human Trafficking

SALT LAKE CITY, July 15, 2024 /PRNewswire/ -- Parker Migliorini International (PMI Foods) just announced a…

27 mins ago

PausePoint Helps Employees and Professionals Prioritize Mental Health

PausePoint, a new mindfulness and wellbeing app designed to help professionals reclaim time, launches officially.…

27 mins ago

CareMagnus Bridges the Gaps in Multi-Channel Care

CareMagnus enhances the multi-channel and person-centred care continuum with its intelligent care management cloud platform.…

27 mins ago

Pharmaceutical Quality Management Systems Market to Be Worth $4.59 Billion by 2031 – Exclusive Report by Meticulous Research®

REDDING, Calif., July 15, 2024 /PRNewswire/ -- According to a new market research report titled, 'Pharmaceutical…

27 mins ago

Electrosurgical Devices Market to Reach USD 10.4 Billion by 2034, Fueled by Advanced Technology Ensuring Precision and Safety | Transparency Market Research

The rise in minimally invasive surgeries is a key driver for the global electrosurgical devices market…

27 mins ago